Monoclonal Antibodies Targeting TLR4/MD-2 Complex
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective modulation of signaling mediated by the TLR4/MD-2 complex, which is crucial for addressing disorders related to aberrant immune responses and inflammation.
Innovation Solution
Development of monoclonal antibodies, including humanized antibodies, that specifically bind to the TLR4/MD-2 receptor complex, inhibiting LPS-induced pro-inflammatory cytokine production by neutralizing the receptor activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional methods are used to address immune response disorders, then treatment options are limited, but effective modulation of TLR4/MD-2 signaling is achieved
Solution Approach 1:
The patent segments the TLR4 signaling pathway into distinct targets: TLR4 receptor itself, MD-2 accessory protein, and their complex formation. Different monoclonal antibodies are designed to bind to specific epitopes on TLR4, MD-2, or the TLR4/MD-2 complex interface, enabling selective modulation of signaling at different levels of the pathway.
Solution Approach 2:
Monoclonal antibodies serve as intermediary molecules that bind to TLR4/MD-2 complex and prevent LPS from activating the receptor. The antibodies act as mediators between the harmful LPS and the immune system, blocking the interaction without directly affecting LPS or the immune cells themselves.
2Object-affected harmful factors
If monoclonal antibodies are developed to bind TLR4/MD-2 complex, then LPS-induced cytokine production is inhibited, but specificity and binding conditions vary among different antibodies
Solution Approach 1:
Different monoclonal antibodies are engineered with distinct specificities: some bind TLR4 independently of MD-2, others bind only when MD-2 is present, and some bind MD-2 but require TLR4. This local differentiation in binding properties allows selection of appropriate antibodies for specific therapeutic contexts and research questions.
Solution Approach 2:
The patent varies multiple parameters among the antibody family: binding affinity, epitope location, dependence on MD-2 presence, and ability to block signaling. These parameter variations are systematically characterized to match specific therapeutic needs and experimental requirements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies significantly inhibit LPS-induced pro-inflammatory cytokine production, offering a therapeutic approach to treat pathologies associated with aberrant TLR4/MD-2 activation and inflammation.
Implementation Method 1
monoclonal antibodies that specifically bind to the TLR4/MD-2 receptor complex, inhibiting LPS-induced pro-inflammatory cytokine production by neutralizing the receptor activation
Implementation Method 2
inhibiting LPS-induced pro-inflammatory cytokine production by neutralizing the receptor activation
Data Source
AI summary
This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the humanized monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins, methods of expressing and purifying soluble chimeric proteins, and methods of using soluble chimeric proteins as therapeutics, in screening assays and in the production of antibodies.